James M. Daly

Former Chief Commercial Officer & Executive Vice President at Incyte Corp.

James M. Daly

James M. Daly

Former Chief Commercial Officer & Executive Vice President at Incyte Corp.

Overview
RelSci Relationships

2917

Number of Boards

7

Birthday

1962

Age

58

Contact Data
Trying to get in touch with James M. Daly? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals James M. Daly likely has professional access to. A relationship does not necessarily indicate a personal connection.

President, Chief Executive Officer & Member of the Board of Directors at Halozyme Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer at ACADIA Pharmaceuticals, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Chairman at Coherus BioSciences, Inc.

Relationship likelihood: Strong

Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

President & Chief Executive Officer at Bellicum Pharmaceuticals Inc.

Relationship likelihood: Strong

Former Senior Vice President-Worldwide Safety & Regulatory at Pfizer, Inc.

Relationship likelihood: Strong

Former Chief Financial Officer at INAMED Corp.

Relationship likelihood: Strong

Chief Technology Officer at Coherus BioSciences, Inc.

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Madrigal Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer at RaNA Therapeutics, Inc.

Relationship likelihood: Strong

Paths to James M. Daly
Potential Connections via
Relationship Science
You
James M. Daly
Former Chief Commercial Officer & Executive Vice President at Incyte Corp.
Education
Undergraduate Degree in Pharmacy
Class of 1985

University at Buffalo, The State University of New York, also commonly known as the University of Buffalo (abbreviated UB), University of Buffalo or SUNY Buffalo, is a public research university with multiple campuses located in Buffalo and Amherst, New York, United States. The university was founded in 1846 as a private college, but in 1962 was absorbed into the State University of New York (SUNY) system. By enrollment, UB is the largest of SUNY's four comprehensive university centers, and also the largest public university in the northeastern United States (comprising New York state and the New England region). In addition, by either endowment or research funding, UB is also the largest one of SUNY's four comprehensive flagship university centers.

Career History
Chief Commercial Officer & Executive Vice President
2012 - 2015

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

Senior Vice President
2002 - Prior

Amgen Ventures LLC invests in biotechnology companies located in North America, Europe and the UK. It focuses companies operating in the fields of discovering and developing human therapeutics. It make financing for early stage capital requirements and invests up to $3 to $5 million per round with $15 million over the life of the company.

Vice President & General Manager-Oncology Business Unit
2001 - 2011

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Political Donations
$1,000
2011

Senator from Washington

$1,000
2010

Former Representative from California's 24th Congressional District

Public Holdings
Restricted data only for RelSci Professional users.
Events
Speaker
New York City, NY
2013 UBS Global Healthcare Conference

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by James M. Daly. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of James M. Daly's profile does not indicate a business or promotional relationship of any kind between RelSci and James M. Daly.